e-Article
Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors.
Document Type
Article
Author
Source
Subject
*PHOTOSENSITIVITY disorders
*PALMOPLANTAR keratoderma
*KERATOSIS
*DRUG side effects
*SKIN disease prevention
*
*
*
*
Language
ISSN
0001-5555
Abstract
The article presents a study regarding the cutaneous toxicities developed during selective anti-BRAF therapies, including the role of combination with MEK inhibitors in preventing these toxicities. Several inhibitors are tested such as vemurafenib, dabrafenib, and dabrafenib-trametinib combined treatment. Particular focus is also given to skin toxicities such as photosensitivity, palmoplantar keratoderma (PPK), and keratosis pilaris (KP).